Amid heightened public concern, the cost of prescription drugs is the focus of renewed attention by the Trump administration, the Biden campaign and lawmakers in Congress and state capitals. Proposed actions range from sweeping health care system changes to targeted initiatives that could affect Medicare, Medicaid and private insurance. See KFF’s research, analysis and public opinion data, as well as Kaiser Health News’ journalism, related to prescription drugs and their costs.

  • Your Selections:

Refine Results

date

Topics

Content Type

Tags

State Medicaid Management of Prescription Drugs for HIV Treatment and Prevention

This data note, primarily based on a survey of state Medicaid pharmacies, reviews cost-containment policies and protections as they relate to antiretrovirals for treatment and prevention of HIV.

Issue Brief Read More

Insulin Costs and Coverage in Medicare Part D

In light of heightened attention to insulin and the Trump Administration’s new Part D model to address out-of-pocket costs for insulin for Medicare beneficiaries, we analyzed out-of-pocket spending on insulin by beneficiaries enrolled in Part D drug plans, variation in Part D plan formulary coverage and tier placement of insulin products, and trends in prices for insulin.

Issue Brief Read More

How State Medicaid Programs are Managing Prescription Drug Costs: Results from a State Medicaid Pharmacy Survey for State Fiscal Years 2019 and 2020

This report summarizes results from a Medicaid pharmacy benefit survey of all 50 states and the District of Columbia (DC) conducted by Kaiser Family Foundation and Health Management Associates in 2019.

Report Read More

Examining Medicare Part D Policies for Extended Supplies of Medication

Medicare Part D plan sponsors, which provide drug coverage to 45 million older adults and people with disabilities, have the option to relax their ‘refill too soon’ restrictions in response to the COVID-19 pandemic, as part of efforts to ensure adequate access to medications in disasters or emergencies. This analysis examines the share of Part D enrollees who currently have access to extended supplies of generic, brand-name, and specialty-tier drugs covered by their plan in 2020, prior to relaxation of any early-fill restrictions in response to the COVID-19 outbreak.

Issue Brief Read More

10 FAQs on Prescription Drug Importation

These FAQs provide background on prescription drug importation, including how the U.S. currently regulates importation and why it hasn’t been successfully implemented before. These FAQs also describe the newest importation proposals, both by the Trump Administration and at the state level, how these proposals seek to address concerns with prior proposals, and how stakeholders are viewing these newest proposals

Issue Brief Read More

Questions about Prescription Drug Importation? KFF Has Answers

With lowering prescription drug costs a top priority for Americans, the Trump Administration, presidential candidates, members of Congress, and several states are proposing to allow the importation of drugs from abroad, chiefly Canada. The idea of allowing drugs to be imported from Canada and other countries is popular with Americans…

News Release Read More

Visualizing Health Policy: US Statistics on Surprise Medical Billing

This infographic examines public opinion on surprise medical billing in the United States as part of the Visualizing Health Policy infographic series, produced in partnership with the Journal of the American Medical Association (JAMA).

Infographic Read More
The Henry J. Kaiser Family Foundation

Visualizing Health Policy: US Statistics on Surprise Medical Billing

This Visualizing Health Policy infographic looks at the experience of unexpected or “surprise” medical bills in the United States. Out-of-network charges typically expose individuals to higher cost-sharing when they use services, and may lead to balance billing – in which providers bill patients directly, and often unexpectedly, at a higher…

News Release Read More